{"product_id":"new-immune-cell-therapies-for-ovarian-cancer-what-patients-need-to-know","title":"New Immune Cell Therapies for Ovarian Cancer: What Patients Need to Know","description":"\u003cp\u003eThis review article summarizes how adoptive cell therapy (ACT) is being developed to treat ovarian cancer, the most lethal gynecological cancer worldwide. The authors describe four main types of ACT. These are tumor-infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR-T), natural killer (NK) cells, and newer approaches such as TCR-T, CIK cells, and gamma-delta T cells. The authors explain how each type works against ovarian tumors. The article reports specific clinical trial results. These results include response rates ranging from 55% to 100% in some small studies. The article also details the major barriers that still limit these treatments. These barriers include the immunosuppressive tumor microenvironment and antigen heterogeneity. The authors conclude that ACT has transformative potential for ovarian cancer but requires further optimization before it can become a standard treatment option.\u003c\/p\u003e\n\n\u003ch1\u003eNew Immune Cell Therapies for Ovarian Cancer: What Patients Need to Know\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n\u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why Ovarian Cancer Needs New Treatments\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#what-is-act\"\u003eWhat Is Adoptive Cell Therapy?\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#how-act-works\"\u003eHow Adoptive Cell Therapy Works\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#nk-cells\"\u003eNatural Killer Cells and Their Role in Adoptive Cell Therapy\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#microenvironment\"\u003eThe Ovarian Cancer Immune Microenvironment: A Major Barrier\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#til\"\u003eTumor-Infiltrating Lymphocyte (TIL) Therapy in Ovarian Cancer\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#car-t\"\u003eCAR-T Cell Therapy in Ovarian Cancer\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#nk-therapy\"\u003eNK Cell Therapy in Ovarian Cancer\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#other-act\"\u003eOther Types of Adoptive Cell Therapy in Ovarian Cancer\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#comparison\"\u003eComparison of Major Adoptive Cell Therapy Approaches\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#conclusion\"\u003eConclusion and Future Directions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of This Review\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#recommendations\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAdoptive cell therapy is not yet standard for ovarian cancer; it is experimental and mainly available through clinical trials.\u003c\/li\u003e\n\u003cli\u003eReported response rates ranged from 55% to 100% in some small studies, so results may not hold in larger trials.\u003c\/li\u003e\n\u003cli\u003eCytokine release syndrome is a possible CAR-T side effect, though in ovarian cancer it appears less frequent and less severe than in blood cancers.\u003c\/li\u003e\n\u003cli\u003eThe immunosuppressive tumor microenvironment, antigen heterogeneity, and physical barriers limit how well these therapies work in ovarian cancer.\u003c\/li\u003e\n\u003cli\u003eCombining adoptive cell therapy with immune checkpoint inhibitors, chemotherapy, targeted therapy, or anti-angiogenic drugs is being explored to improve outcomes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why Ovarian Cancer Needs New Treatments\u003c\/h2\u003e\n\n\u003cp\u003eOvarian cancer is one of the three major cancers of the female reproductive system. It remains a leading cause of death from gynecological cancers worldwide.\u003c\/p\u003e\n\n\u003cp\u003eThe current standard treatment for ovarian cancer centers on cytoreductive surgery (surgery to remove as much tumor as possible) followed by platinum-based adjuvant chemotherapy (chemotherapy given after surgery). This approach can produce favorable initial responses in some patients. However, its overall benefit is limited by several persistent problems.\u003c\/p\u003e\n\n\u003cp\u003eMost patients receive their diagnosis at an advanced stage. At that point, cancer has often spread widely throughout the abdominal cavity, and a high tumor burden frequently makes complete surgical removal impossible. Even after standard treatment with surgery and chemotherapy, the majority of patients experience a relapse within 2 years. This relapse is often accompanied by chemoresistance (the cancer stops responding to chemotherapy), which drives disease progression and contributes to poor survival outcomes.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, some patients cannot undergo surgery at all. This may be because the cancer has spread too widely or because the patient's physical condition is too compromised. These limitations highlight an urgent need for new treatment strategies. Ideal new treatments would be more effective, less toxic, and capable of improving long-term prognosis for patients with ovarian cancer.\u003c\/p\u003e\n\n\u003cp\u003eImmunotherapy has emerged as the fourth major pillar of cancer treatment, alongside surgery, chemotherapy, and radiotherapy. Broadly, immunotherapy includes immune checkpoint inhibitors (ICIs), adoptive cell immunotherapy (ACT), cytokine therapy, and cancer vaccines. Among these, ACT is considered one of the most promising immunotherapies because of its high efficacy and low toxicity. This review summarizes the mechanisms of ACT and the latest advances in its application to ovarian cancer. The goal is to offer insights for optimizing clinical treatment strategies and to guide future research into innovative therapies.\u003c\/p\u003e\n\n\u003ch2 id=\"what-is-act\"\u003eWhat Is Adoptive Cell Therapy?\u003c\/h2\u003e\n\n\u003cp\u003eAdoptive cell therapy represents a paradigm-shifting immunotherapeutic approach. In this treatment, immune cells are harvested from patients (autologous) or from donors (allogeneic). These cells undergo ex vivo expansion (growth outside the body) and functional reprogramming. They are then reinfused into the patient to enhance specific tumor recognition and cell killing.\u003c\/p\u003e\n\n\u003cp\u003eBy increasing the immunogenicity of tumor cells (making them more visible to the immune system) and reversing the immunosuppressive microenvironment, ACT stimulates and sustains the body's long-lasting anti-tumor immune response.\u003c\/p\u003e\n\n\u003cp\u003eClinically, ACT has demonstrated profound efficacy across diverse malignancies. For instance, chimeric antigen receptor T-cell therapy (CAR-T) has achieved a complete response rate (CRR) of over 80% in patients with acute lymphocytic leukemia (ALL). However, the therapeutic performance of ACT differs substantially between blood cancers and solid tumors.\u003c\/p\u003e\n\n\u003cp\u003eIn hematologic cancers (blood cancers), target antigens are often more uniformly expressed. Malignant cells are more readily accessible in the circulation or bone marrow. Infused effector cells encounter fewer physical barriers to trafficking and target engagement.\u003c\/p\u003e\n\n\u003cp\u003eSolid tumors present a different picture. They are characterized by substantial intertumoral and intratumoral antigen heterogeneity (different tumor cells have different markers). They also have spatially restricted immune infiltration and a highly suppressive tumor microenvironment. Together, these factors constrain the persistence, penetration, and cytotoxic efficacy of adoptively transferred cells.\u003c\/p\u003e\n\n\u003cp\u003eThese constraints are particularly relevant in ovarian cancer. Stromal desmoplasia (dense scar-like tissue around the tumor), aberrant vasculature (abnormal blood vessels), immunosuppressive cytokines, and inhibitory immune cell populations create a hostile niche for ACT. Thus, although ACT has transformed the treatment landscape of blood cancers, its successful translation to ovarian cancer requires additional strategies. These strategies must address antigen escape, poor tumor homing, and immune suppression.\u003c\/p\u003e\n\n\u003cp\u003eEmerging non-invasive therapeutic approaches may provide an important means of augmenting ACT responsiveness. The thermal effect induced by non-invasive strategies can enhance T-cell infiltration into tumors and the killing effect on tumor cells. This has been shown in melanoma and orthotopic liver cancer mouse models during ACT treatment. Similarly, cryo-thermal therapy can remodel the tumor immune microenvironment, significantly improving the efficacy of ACT.\u003c\/p\u003e\n\n\u003cp\u003eThese treatment methods not only enhance the specific recognition and killing ability of immune cells against tumors. They also overcome immunosuppression in the tumor microenvironment.\u003c\/p\u003e\n\n\u003ch2 id=\"how-act-works\"\u003eHow Adoptive Cell Therapy Works\u003c\/h2\u003e\n\n\u003cp\u003eACT can be divided into HLA-dependent ACT and HLA-independent ACT. HLA (human leukocyte antigen) molecules present antigens to the immune system.\u003c\/p\u003e\n\n\u003cp\u003eHLA-dependent ACT recognizes tumor antigens presented by HLA molecules through T-cell receptors. This category includes T-cell receptor engineered T-cell therapy (TCR-T) and tumor-infiltrating lymphocyte therapy (TIL).\u003c\/p\u003e\n\n\u003cp\u003eHLA-independent ACT recognizes and kills tumor cells through mechanisms that do not require HLA molecules. This category includes CAR-T, NK cell therapy, and other HLA-independent ACT approaches.\u003c\/p\u003e\n\n\u003cp\u003eThe antitumor activity of ACT is mediated by the in vivo persistence and function of ex vivo expanded or genetically engineered immune cells. Therapeutic efficacy is largely determined by their capacity for activation, tumor-specific recognition, proliferation, and cytotoxic effector responses.\u003c\/p\u003e\n\n\u003cp\u003eT cells are genetically engineered to acquire the ability to efficiently recognize tumor antigens. They do this by expressing chimeric antigen receptors (CAR) or specific T cell receptors. CAR-T cells directly recognize tumor cell surface antigens (such as CD19 and MUC16) through single-chain variable fragments (scFv). TCR-T cells recognize intracellular antigen peptides presented by MHC molecules.\u003c\/p\u003e\n\n\u003cp\u003eThis recognition event triggers intracellular activation programs that drive cytotoxic responses. These responses include the release of perforin and granzymes, engagement of death-receptor pathways, and the production of effector cytokines such as IFN-gamma and TNF-alpha. Together, these promote both direct tumor-cell killing and broader immune recruitment.\u003c\/p\u003e\n\n\u003cp\u003eIn contrast to T-cell-based ACT, NK cells exert antitumor activity in a non-antigen-specific, MHC-independent manner. They do this through \"missing-self\" surveillance together with signals derived from cellular stress ligands.\u003c\/p\u003e\n\n\u003cp\u003eHowever, the efficacy of ACT is frequently constrained by the immunosuppressive tumor microenvironment. Immunoregulatory cell populations, including regulatory T cells and tumor-associated macrophages, together with inhibitory mediators such as PD-L1 and TGF-beta, can markedly impair effector cell activation, infiltration, persistence, and cytotoxicity.\u003c\/p\u003e\n\n\u003cp\u003eTo overcome these barriers, ACT enhances T cell proliferation and anti-exhaustion capabilities by introducing costimulatory molecules (CD28 and 4-1BB). It also combines immune checkpoint inhibitors (PD-1\/PD-L1 blockers) to reverse the immunosuppressive state.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, ACT can improve T cell adaptability and infiltration in the tumor microenvironment by targeting metabolic reprogramming to enhance glycolytic capacity. It can also degrade the tumor stromal barrier through secretion of matrix-remodeling approaches. These strategies effectively counter tumor immune evasion mechanisms such as antigen loss, upregulation of immune checkpoints, and physical barriers.\u003c\/p\u003e\n\n\u003cp\u003eOverall, ACT enhances T cell anti-tumor activity through multi-layered mechanisms, remodels the tumor microenvironment, and provides new strategies to overcome tumor immune evasion. This demonstrates significant clinical potential.\u003c\/p\u003e\n\n\u003ch2 id=\"nk-cells\"\u003eNatural Killer Cells and Their Role in Adoptive Cell Therapy\u003c\/h2\u003e\n\n\u003cp\u003eNatural killer (NK) cells are a type of immune cell that can kill tumor cells without prior sensitization. Unlike T cells, NK cells do not need to recognize a specific antigen to attack. They use \"missing-self\" surveillance, meaning they detect cells that lack normal identity markers.\u003c\/p\u003e\n\n\u003cp\u003eNK cells also respond to signals from cellular stress ligands. This allows them to target cancer cells that have lost MHC class I molecules, a common way tumors evade T-cell attack.\u003c\/p\u003e\n\n\u003cp\u003eIn the context of ACT, NK cells offer several advantages. They have a low risk of graft-versus-host disease (GVHD), which makes allogeneic (donor-derived) use possible. This means NK cell therapies could potentially be manufactured in advance and stored for off-the-shelf use.\u003c\/p\u003e\n\n\u003cp\u003eHowever, NK cells also face challenges in ovarian cancer. They have limited persistence in the body, weak tumor homing ability, and are suppressed by the tumor microenvironment. Researchers are working to overcome these limitations through genetic engineering, including the development of chimeric antigen receptor NK (CAR-NK) cells.\u003c\/p\u003e\n\n\u003ch2 id=\"microenvironment\"\u003eThe Ovarian Cancer Immune Microenvironment: A Major Barrier\u003c\/h2\u003e\n\n\u003cp\u003eThe immunosuppressive microenvironment of ovarian cancer has unique pathological features. These features constitute a major barrier to the efficacy of ACT.\u003c\/p\u003e\n\n\u003cp\u003eInhibitory immune cells such as regulatory T cells and tumor-associated macrophages account for 30% of the immunosuppressive microenvironment. These cells directly suppress T cell function through IL-10 and TGF-beta.\u003c\/p\u003e\n\n\u003cp\u003eImmune checkpoints like PD-L1 are overexpressed in 60% of advanced ovarian cancer patients. This accelerates T cell exhaustion.\u003c\/p\u003e\n\n\u003cp\u003eTumor antigen heterogeneity, including dynamic fluctuations in MUC16 expression, undermines stable target recognition. Downregulation of major histocompatibility complex class I (MHC-I) further compromises immune surveillance. This facilitates escape from effector-cell-mediated killing.\u003c\/p\u003e\n\n\u003cp\u003eBesides, dense fibrotic stroma and abnormal vascular networks hinder cell infiltration. These physical barriers make it difficult for immune cells to reach the tumor.\u003c\/p\u003e\n\n\u003cp\u003eTo address the major translational barriers facing ACT in ovarian cancer, current efforts are centered on refining tumor-targeting specificity and reinforcing T-cell functional competence. Representative strategies include dual-antigen CAR-T systems targeting molecules such as MUC16 and mesothelin. Neoantigen-informed TCR-T designs are intended to broaden tumor recognition while minimizing immune escape.\u003c\/p\u003e\n\n\u003cp\u003eConcurrently, next-generation engineering approaches seek to improve T-cell persistence and effector durability. These approaches use optimized co-stimulatory signaling, particularly 4-1BB-based constructs. Metabolic reprogramming strategies support mitochondrial integrity and long-term cellular fitness within the hostile tumor microenvironment.\u003c\/p\u003e\n\n\u003cp\u003eImmunosuppression reversal strategies include combining PD-1 inhibitors or A2aR antagonists (CPI-444) to block inhibitory signals.\u003c\/p\u003e\n\n\u003ch2 id=\"til\"\u003eTumor-Infiltrating Lymphocyte (TIL) Therapy in Ovarian Cancer\u003c\/h2\u003e\n\n\u003cp\u003eTIL therapy is an immunotherapeutic approach that involves isolating lymphocytes from tumor tissue. These cells are expanded in a culture medium enriched with IL-2 to obtain a large number of highly purified TILs. The cells are then reinfused into the patient to enhance the antitumor activity of immune cells.\u003c\/p\u003e\n\n\u003cp\u003eIn ovarian cancer, interest in TIL-based therapy has increased steadily. Early clinical trials have confirmed the preliminary efficacy of TIL therapy.\u003c\/p\u003e\n\n\u003cp\u003eAoki et al. reported an objective response rate (ORR) of 71% with monotherapy in advanced patients. Combination with chemotherapy further increased the ORR to 70%. In postoperative adjuvant therapy, TIL therapy achieved higher overall survival than the control group.\u003c\/p\u003e\n\n\u003cp\u003eIn recent years, research on TIL therapy has increasingly focused on overcoming the immunosuppressive tumor microenvironment and exploring combination strategies. TIL combined with IL-2 treatment could stabilize or shrink target lesions in platinum-resistant patients. However, the emergence of new lesions indicated incomplete reversal of local immunosuppression.\u003c\/p\u003e\n\n\u003cp\u003eTo enhance efficacy, the combination of TIL therapy with immune checkpoint inhibitors (PD-1\/PD-L1 inhibitors) is being widely investigated. A clinical trial in breast cancer patients demonstrated that TIL combined with PD-1 inhibitors significantly improved ORR with manageable safety. Additionally, combinations of TIL therapy with chemotherapy or targeted therapy are under exploration, showing promising synergistic effects.\u003c\/p\u003e\n\n\u003cp\u003eCurrently, multiple clinical trials are further validating the efficacy and safety of TIL therapy. For example, in the NCT03610490 trial, autologous MDA-TIL treatment in platinum-resistant patients resulted in a median overall survival of 4.9 months and a disease control rate (DCR) of 67%.\u003c\/p\u003e\n\n\u003ch2 id=\"car-t\"\u003eCAR-T Cell Therapy in Ovarian Cancer\u003c\/h2\u003e\n\n\u003cp\u003eA key aspect of CAR-T therapy is identifying ideal tumor-specific antigens. Currently, clinical studies targeting various CAR recognition sites in cancers are underway. These include FR-alpha (NCT00019136), EGFR (NCT01869166), and HER2 (NCT01935843).\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, new targets such as CD44, CD133, and ALDH — markers associated with ovarian cancer stem cells — are gradually gaining attention. Surface markers of cancer-associated fibroblasts (CAF) and tumor vascular endothelial cells in the tumor microenvironment are also being explored. Exploration of these targets will provide new directions for optimizing CAR-T therapy in ovarian cancer treatment.\u003c\/p\u003e\n\n\u003cp\u003eIn terms of clinical research, advanced ovarian cancer patients with platinum-resistant disease showed that 67% of patients experienced reduced tumor burden, with a disease control rate of 86%.\u003c\/p\u003e\n\n\u003cp\u003eIt is reported that DAP-CAR-T cells targeting mesothelin achieved a 100% disease control rate in six patients with mesothelin (MSLN)-positive advanced recurrent refractory ovarian cancer. This included two cases of partial response and four cases of stable disease, with a median overall survival of 11 months.\u003c\/p\u003e\n\n\u003cp\u003eTo further improve the efficacy of CAR-T cells in ovarian cancer, researchers have optimized the structure and function of CAR-T cells in multiple ways. CAR-T cell therapy targeting tumor-associated glycoprotein-72 (TAG-72) demonstrated significant anti-tumor efficacy in a mouse model, with a complete response rate of 40%.\u003c\/p\u003e\n\n\u003cp\u003eThe addition of IL-12 helped T cells kill tumor cells, enter the bloodstream, and eliminate distant metastases. Meanwhile, the rational use of cytokines can significantly enhance CAR-T cell function. For example, CAR-T cells with a memory phenotype generated through short-term co-culture with IL-2 exhibited greater persistence and anti-tumor activity in vivo. IL-15 and IL-7 promote the in vitro expansion of CAR-T cells and enhance their anti-tumor capability. Inhibiting IL-10 in the tumor microenvironment can reverse immunosuppression, improving the survival and anti-tumor effects of CAR-T cells.\u003c\/p\u003e\n\n\u003cp\u003eResearchers have developed bispecific CAR-T cells that can simultaneously recognize two different tumor antigens, such as MUC16 and mesothelin. This reduces the likelihood of tumor escape.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, combination therapy is an important strategy to improve the efficacy of CAR-T. Studies indicate that combining CAR-T cells with immune checkpoint inhibitors (PD-1\/PD-L1 inhibitors) can reverse the immunosuppressive state of the tumor microenvironment and enhance T cell activity. CAR-T cells combined with the anti-angiogenic drug apatinib reduced tumor lesions and lowered CA125 levels. This suggests the potential value of combination therapy in ovarian cancer.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, while radiotherapy and chemotherapy inhibit T cell function, they can also expose more tumor targets. This enhances the therapeutic effect of CAR-T cells. For example, the combination of paclitaxel and HER2-CAR-T therapy exhibits synergistic anti-tumor effects. This strategy not only directly kills tumor cells but also creates a more favorable treatment environment for CAR-T cells by altering the tumor microenvironment. This offers more possibilities for ovarian cancer treatment.\u003c\/p\u003e\n\n\u003cp\u003eDespite substantial progress in CAR-T therapy for ovarian cancer, several major challenges continue to limit its broader clinical translation.\u003c\/p\u003e\n\n\u003cp\u003eFirst, the marked heterogeneity of ovarian cancer and its profoundly immunosuppressive tumor microenvironment can impair T-cell trafficking, persistence, and cytotoxic function. This reduces therapeutic efficacy.\u003c\/p\u003e\n\n\u003cp\u003eSecond, treatment-related toxicities remain an important clinical concern. Among these, cytokine release syndrome (CRS) is one of the most recognized immune-mediated adverse events following adoptive cell therapy.\u003c\/p\u003e\n\n\u003cp\u003eCRS is primarily driven by rapid immune activation after CAR-T-cell engagement with tumor cells. This results in excessive production of inflammatory mediators such as IL-6, IL-1, IFN-gamma, TNF-alpha, and granulocyte-macrophage colony-stimulating factor (GM-CSF). This inflammatory cascade may induce fever, hypotension, capillary leakage, coagulopathy, and, in severe cases, multiorgan dysfunction.\u003c\/p\u003e\n\n\u003cp\u003eIn solid tumors such as ovarian cancer, CRS appears to be generally less frequent and often less severe than that observed in hematologic malignancies. This is likely because of lower circulating tumor burden, restricted CAR-T expansion, and physical barriers within the tumor microenvironment. Nevertheless, CRS remains clinically relevant, particularly as newer CAR designs, regional delivery strategies, and combination regimens enhance T-cell activation and intratumoral accumulation.\u003c\/p\u003e\n\n\u003cp\u003eMore importantly, identifying highly expressed specific targets in tumors is key to further enhancing the effectiveness of CAR-T therapy.\u003c\/p\u003e\n\n\u003ch2 id=\"nk-therapy\"\u003eNK Cell Therapy in Ovarian Cancer\u003c\/h2\u003e\n\n\u003cp\u003eNK cell therapy has emerged as a promising ACT strategy in ovarian cancer. In preclinical models, IL-15-based approaches enhance NK-cell activation, increase granzyme and IFN-gamma release, and improve control of intraperitoneal ovarian tumors.\u003c\/p\u003e\n\n\u003cp\u003eIn a recent phase I trial of intraperitoneally infused stem-cell-derived allogeneic NK cells in recurrent epithelial ovarian cancer, treatment was well tolerated without severe toxicity. Five of 7 patients showed transient reductions in CA125 levels. One patient achieved radiologically stable disease and a progression-free survival of 9 months.\u003c\/p\u003e\n\n\u003cp\u003eEarlier translational clinical data summarized in recent reviews also suggest that responses to allogeneic NK-cell infusion in ovarian cancer are heterogeneous. Responses ranged from temporary disease stabilization to progressive disease. This underscores the need for further optimization of cell source, dosing schedule, and microenvironmental support.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, another clinical trial assessed the activity of intraperitoneally infused expanded allogeneic NK cells in ovarian and fallopian tube cancers, with promising results anticipated.\u003c\/p\u003e\n\n\u003cp\u003eWith advancements in genetic engineering, chimeric antigen receptor NK (CAR-NK) cells have become a research hotspot. Researchers designed a dual CAR-NK cell targeting CD24 and CD28. This cell not only directly eliminates ovarian cancer cells but also exhibits strong cytotoxicity against ovarian cancer stem cells.\u003c\/p\u003e\n\n\u003cp\u003eIn parallel, engineered NK-cell platforms are gaining momentum. Preclinical studies have shown that anti-CLDN6 CAR-NK cells directly killed ovarian cancer cells in vitro and effectively reduced tumor growth and metastasis in subcutaneous and intraperitoneal ovarian cancer animal models.\u003c\/p\u003e\n\n\u003cp\u003eCurrently, human embryonic stem cells and induced pluripotent stem cells are the primary sources of NK cells in clinical trials. Their scalable cultivation techniques provide a foundation for clinical translation.\u003c\/p\u003e\n\n\u003ch2 id=\"other-act\"\u003eOther Types of Adoptive Cell Therapy in Ovarian Cancer\u003c\/h2\u003e\n\n\u003cp\u003eIn addition to TIL, CAR-T, and NK cell therapies, several other ACT approaches are being investigated in ovarian cancer.\u003c\/p\u003e\n\n\u003cp\u003eTCR-T cell therapy involves genetically engineering T cell receptors to recognize tumor antigens presented by MHC molecules. Compared to CAR-T, TCR-T can target intracellular antigens (NY-ESO-1, MAGE-A). This expands the range of target selection.\u003c\/p\u003e\n\n\u003cp\u003eThe results of a Phase I\/II clinical trial on TCR-T cell therapy showed that the ORR reached 55% in ovarian cancer patients treated with NY-ESO-1 TCR-T. Some patients achieved long-term disease stabilization.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, cytokine-induced killer (CIK) cell therapy involves the in vitro culture of peripheral blood mononuclear cells induced by cytokines. This produces a heterogeneous cell population with characteristics of both NK cells and T cells.\u003c\/p\u003e\n\n\u003cp\u003eThe clinical application of CIK cells in ovarian cancer primarily focuses on combination with chemotherapy or targeted therapy. Studies have shown that CIK cell therapy has a high safety profile but relatively weak efficacy and lacks specificity.\u003c\/p\u003e\n\n\u003cp\u003eGamma-delta (gd) T cell therapy utilizes a special subset of T cells that recognize tumor cells in a non-MHC restricted manner. The potential application of gd T cells in ovarian cancer has garnered significant attention, particularly for their effect on cancer stem cells. However, the expansion of gd T cells is challenging, and their efficacy requires further validation.\u003c\/p\u003e\n\n\u003ch2 id=\"comparison\"\u003eComparison of Major Adoptive Cell Therapy Approaches\u003c\/h2\u003e\n\n\u003cp\u003eThe review provides a detailed comparison of the major ACT modalities in ovarian cancer. Each approach has distinct advantages and challenges.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTumor-Infiltrating Lymphocytes (TIL):\u003c\/strong\u003e HLA-dependent. Targets a broad range of tumor-associated antigens. Uses endogenous TCR-mediated recognition and cytotoxicity via perforin\/granzyme and cytokine secretion. Clinical advantages include personalized treatment, polyclonal T cell response, and effectiveness in antigen-heterogeneous tumors. Challenges include limited TIL infiltration, expansion difficulty, local immunosuppression, and response variability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eChimeric Antigen Receptor T Cells (CAR-T):\u003c\/strong\u003e HLA-independent. Targets specific surface antigens with high specificity (MUC16, mesothelin, FR-alpha). Uses CAR-mediated surface antigen recognition and cytotoxic T cell activation. Advantages include potent cytotoxicity, genetic programmability, and MHC-unrestricted action. Challenges include tumor antigen heterogeneity, poor T cell infiltration, off-tumor toxicity, and cytokine release syndrome.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTCR-Engineered T Cells (TCR-T):\u003c\/strong\u003e HLA-dependent. Targets intracellular peptides with high specificity (NY-ESO-1, MAGE-A4). Recognizes intracellular peptides via engineered TCRs presented by MHC. Advantages include targeting intracellular antigens and a broader antigen pool. Challenges include MHC restriction, tumor MHC-I downregulation, and risk of cross-reactivity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNatural Killer (NK) Cells:\u003c\/strong\u003e HLA-independent. Has low-to-medium specificity through non-specific, missing-self recognition. Uses natural cytotoxicity, ADCC, and cytokine production (IFN-gamma, TNF-alpha). Advantages include innate tumor recognition, low GVHD risk, and off-the-shelf potential. Challenges include limited persistence, weak tumor homing, and suppression by the tumor microenvironment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCAR-NK Cells:\u003c\/strong\u003e HLA-independent. Has high specificity (engineered CAR specificity). Uses dual killing mechanisms: CAR-directed killing plus innate cytotoxicity. Advantages include reduced toxicity versus CAR-T and allogeneic use potential. Challenges include expansion and persistence, and limited clinical data in ovarian cancer.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCytokine-Induced Killer (CIK) Cells:\u003c\/strong\u003e Partially HLA-independent. Has low specificity (non-restricted cytotoxicity). Uses mixed T\/NK-like activity with IFN-gamma and granzyme-mediated killing. Advantages include easy generation, safety, and ability to combine with chemo\/targeted drugs. Challenges include low specificity, limited in vivo persistence, and modest efficacy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGamma-Delta (gd) T Cells:\u003c\/strong\u003e HLA-independent. Has low-to-medium specificity (non-peptide phosphoantigen recognition). Uses MHC-unrestricted cytotoxicity and targeting of stress-induced ligands. Advantages include targeting cancer stem cells, broad recognition, and lower risk of immune escape. Challenges include difficult in vitro expansion and limited clinical experience.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"conclusion\"\u003eConclusion and Future Directions\u003c\/h2\u003e\n\n\u003cp\u003eDespite advances in standard therapies, ovarian cancer continues to exhibit poor long-term prognosis. This is due to frequent recurrence, chemoresistance, and an immunosuppressive tumor microenvironment.\u003c\/p\u003e\n\n\u003cp\u003eACT represents a paradigm shift in cancer immunotherapy. It works by harnessing and enhancing the cytotoxic capacity of immune effector cells. This offers targeted and durable responses.\u003c\/p\u003e\n\n\u003cp\u003eAmong ACT modalities, TIL therapy has demonstrated early clinical efficacy. CAR-T cell therapy continues to evolve with dual-target and cytokine-enhanced constructs. NK\/CAR-NK cell therapy offers an off-the-shelf alternative with encouraging safety profiles.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, novel approaches including TCR-T and gd T cells expand the repertoire of intracellular and non-HLA-restricted targets. Combination strategies are also being explored to enhance efficacy.\u003c\/p\u003e\n\n\u003cp\u003eTogether, these insights underscore the transformative potential of ACT in ovarian cancer. They also outline future directions for personalized and scalable immunotherapies.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of This Review\u003c\/h2\u003e\n\n\u003cp\u003eThis article is a mini-review, not a new clinical trial. It summarizes and interprets findings from previously published studies. As a result, the conclusions depend on the quality and design of the original research.\u003c\/p\u003e\n\n\u003cp\u003eMany of the clinical trials described are early-phase studies with small numbers of patients. For example, the DAP-CAR-T study included only six patients. The NK cell trial included only seven patients. Small studies can show promising results that may not hold true in larger trials.\u003c\/p\u003e\n\n\u003cp\u003eThe review does not provide a meta-analysis or systematic pooling of data. It also does not report long-term follow-up data for most of the treatments discussed.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, the review notes that responses to allogeneic NK-cell infusion in ovarian cancer are heterogeneous, ranging from temporary disease stabilization to progressive disease. This variability highlights the need for further optimization.\u003c\/p\u003e\n\n\u003cp\u003eThe authors also acknowledge that gd T cell therapy requires further validation, and that CIK cell therapy has relatively weak efficacy and lacks specificity.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eAdoptive cell therapy is not yet a standard treatment for ovarian cancer. It remains an experimental approach available primarily through clinical trials.\u003c\/p\u003e\n\n\u003cp\u003eHowever, the research summarized in this review shows several promising directions. If you or a loved one is facing ovarian cancer, here are key points to discuss with your oncology team:\u003c\/p\u003e\n\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eAsk about clinical trial eligibility.\u003c\/strong\u003e Multiple clinical trials are testing TIL, CAR-T, NK cell, TCR-T, CIK, and gd T cell therapies in ovarian cancer. Some trials are specifically for platinum-resistant or recurrent disease.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eUnderstand the current standard of care.\u003c\/strong\u003e Cytoreductive surgery followed by platinum-based chemotherapy remains the standard first-line treatment. ACT is being studied as an addition or alternative for patients who do not respond to standard treatment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRecognize the challenges.\u003c\/strong\u003e The immunosuppressive tumor microenvironment, antigen heterogeneity, and physical barriers in ovarian cancer make these treatments less effective than they are in blood cancers. Researchers are actively working to overcome these barriers.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBe aware of side effects.\u003c\/strong\u003e Cytokine release syndrome (CRS) is a possible side effect of CAR-T therapy. In ovarian cancer, CRS appears to be less frequent and less severe than in blood cancers, but it remains a clinical concern.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConsider combination approaches.\u003c\/strong\u003e Research suggests that combining ACT with immune checkpoint inhibitors, chemotherapy, targeted therapy, or anti-angiogenic drugs may improve outcomes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStay informed about new targets.\u003c\/strong\u003e Researchers are exploring new targets such as CD44, CD133, ALDH, CLDN6, and cancer-associated fibroblast markers. These may lead to more effective treatments in the future.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe field is advancing rapidly. The authors conclude that ACT has transformative potential for ovarian cancer. However, more research is needed to make these therapies scalable, personalized, and widely available.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eIs adoptive cell therapy a standard treatment for ovarian cancer?\u003c\/h3\u003e\n\u003cp\u003eNo. Adoptive cell therapy is not yet a standard treatment for ovarian cancer. It remains an experimental approach available primarily through clinical trials. The current standard first-line treatment is cytoreductive surgery followed by platinum-based chemotherapy. Adoptive cell therapy is being studied as an addition or alternative for patients who do not respond to standard treatment.\u003c\/p\u003e\n\u003ch3\u003eWhat is adoptive cell therapy and how does it work?\u003c\/h3\u003e\n\u003cp\u003eAdoptive cell therapy takes immune cells from a patient or donor, grows and reprograms them outside the body, then reinfuses them to help the immune system recognize and attack tumor cells. Types include tumor-infiltrating lymphocytes, CAR-T cells, natural killer cells, TCR-T cells, CIK cells, and gamma-delta T cells. Each works differently against ovarian tumors.\u003c\/p\u003e\n\u003ch3\u003eWhat side effects can adoptive cell therapy cause?\u003c\/h3\u003e\n\u003cp\u003eCytokine release syndrome is a possible side effect of CAR-T therapy. It is driven by rapid immune activation and can cause fever, low blood pressure, capillary leakage, clotting problems, and in severe cases multiorgan dysfunction. In ovarian cancer, cytokine release syndrome appears less frequent and less severe than in blood cancers, but it remains a clinical concern.\u003c\/p\u003e\n\u003ch3\u003eWhat do the response rates in these trials mean?\u003c\/h3\u003e\n\u003cp\u003eResponse rates describe how many patients had their tumor shrink or stop growing in a study. Reported rates ranged from 55% to 100% in some small studies. For example, a DAP-CAR-T study of six patients with mesothelin-positive advanced ovarian cancer reported a 100% disease control rate. Small studies can show promising results that may not hold in larger trials.\u003c\/p\u003e\n\u003ch3\u003eCan I join a clinical trial for adoptive cell therapy?\u003c\/h3\u003e\n\u003cp\u003eMultiple clinical trials are testing TIL, CAR-T, NK cell, TCR-T, CIK, and gamma-delta T cell therapies in ovarian cancer. Some trials are specifically for platinum-resistant or recurrent disease. Ask your oncology team about clinical trial eligibility, because eligibility depends on your cancer type, prior treatments, and overall health.\u003c\/p\u003e\n\u003ch3\u003eWhy is adoptive cell therapy less effective in ovarian cancer than in blood cancers?\u003c\/h3\u003e\n\u003cp\u003eOvarian tumors have an immunosuppressive microenvironment, antigen heterogeneity, and physical barriers such as dense scar-like tissue and abnormal blood vessels. These factors limit how well transferred immune cells persist, reach the tumor, and kill cancer cells. In blood cancers, target antigens are more uniform and cancer cells are more accessible, so adoptive cell therapy works better.\u003c\/p\u003e\n\u003ch3\u003eWhat new targets are being studied for ovarian cancer cell therapy?\u003c\/h3\u003e\n\u003cp\u003eResearchers are exploring targets including CD44, CD133, and ALDH, which are markers linked to ovarian cancer stem cells. Other targets under study include CLDN6 and markers on cancer-associated fibroblasts and tumor blood vessel cells. These may lead to more effective treatments in the future, but they are still being investigated in early research.\u003c\/p\u003e\n\u003ch3\u003eWhen should a patient with ovarian cancer seek a second opinion about adoptive cell therapy?\u003c\/h3\u003e\n\u003cp\u003eAdoptive cell therapy is not yet a standard treatment for ovarian cancer; it remains experimental and is available primarily through clinical trials, including some for platinum-resistant or recurrent disease. Cytoreductive surgery followed by platinum-based chemotherapy remains the standard first-line treatment. A second opinion can help clarify whether a trial of TIL, CAR-T, NK cell, TCR-T, CIK, or gamma-delta T cell therapy is appropriate, and whether combining ACT with immune checkpoint inhibitors, chemotherapy, targeted therapy, or anti-angiogenic drugs may improve outcomes. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Advances in adoptive cell therapy for ovarian cancer.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Zhao N, An Y, Guo S, Xu Z, Shi H, Zhang Z.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthor affiliations:\u003c\/strong\u003e Department of Obstetrics and Gynecology, Affiliated Hospital of Binzhou Medical University, Binzhou, China; Operating Room, Department of Anesthesiology, Affiliated Hospital of Binzhou Medical University, Binzhou, China\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Frontiers in Immunology, Volume 17, Article 1794716\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication date:\u003c\/strong\u003e April 27, 2026\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3389\/fimmu.2026.1794716\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eArticle type:\u003c\/strong\u003e Mini Review\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCopyright:\u003c\/strong\u003e © 2026 Zhao, An, Guo, Xu, Shi and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace consultation with a qualified healthcare provider. Patients should discuss all treatment options with their oncology team.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47828067745948,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0599\/5449\/5644\/files\/ddn-medical-article-new-immune-cell-therapies-for-ovarian-cancer-what-patients-need-to-know-hero.png?v=1793168622","url":"https:\/\/diagnosticdetectives.com\/de\/products\/new-immune-cell-therapies-for-ovarian-cancer-what-patients-need-to-know","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}